Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Asst. Prof. Joleen Hubbard, Assoc. Prof. Yu Sunakawa
Ass. Prof. Joleen Hubbard and Ass. Prof. Yu Sunakawa discuss the Clinical Question: Which targeted drug is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Expert View |
5 min
I agree that this educational programme:
Was valuable to me:
1/3
Other programmes of interest
Other programmes developed by Asst. Prof. Joleen Hubbard

Asst. Prof. Joleen Hubbard
Medical Oncologist
Mayo Cinic Rochester
United States (US)
Other programmes developed by Assoc. Prof. Yu Sunakawa

Assoc. Prof. Yu Sunakawa
Medical Oncologist
St Marianna University
Japan